Last reviewed · How we verify
intravenous nitroglycerin
intravenous nitroglycerin is a Nitrate vasodilator Small molecule drug developed by University of California, San Francisco. It is currently FDA-approved for Acute angina pectoris, Acute myocardial infarction with chest pain, Hypertensive crisis.
Intravenous nitroglycerin is a nitrate vasodilator that releases nitric oxide to relax vascular smooth muscle and reduce preload and afterload on the heart.
Intravenous nitroglycerin is a small molecule that activates soluble guanylate cyclase, a molecular target involved in vascular function. It has been studied in various clinical trials for conditions such as type 2 diabetes mellitus, contrast-induced nephropathy, and severe pre-eclampsia.
At a glance
| Generic name | intravenous nitroglycerin |
|---|---|
| Sponsor | University of California, San Francisco |
| Drug class | Nitrate vasodilator |
| Target | Soluble guanylate cyclase (via nitric oxide) |
| Modality | Small molecule |
| Therapeutic area | Cardiovascular |
| Phase | FDA-approved |
Mechanism of action
Nitroglycerin is metabolized to nitric oxide, which activates guanylate cyclase and increases cyclic GMP levels in vascular smooth muscle cells, leading to vasodilation. This reduces venous return (preload) and systemic vascular resistance (afterload), decreasing myocardial oxygen demand and improving coronary blood flow. The intravenous formulation provides rapid onset and precise titration for acute hemodynamic management.
Approved indications
- Acute angina pectoris
- Acute myocardial infarction with chest pain
- Hypertensive crisis
- Acute heart failure with pulmonary edema
- Perioperative hypertension
Common side effects
- Headache
- Hypotension
- Tachycardia
- Dizziness
- Nausea
- Methemoglobinemia (with prolonged use)
Key clinical trials
- Evaluating the Effects of Nitroglycerin on Heart Function and Urinary Output in Patients With Acute Heart Failure (PHASE4)
- Efficacy and Safety of Renal Denervation on Isolated Diastolic Hypertension (NA)
- Role of Sympathetic Activity and Splanchnic Capacitance in Hypertension (PHASE1)
- Analysis of Coronary Reactivity Testing With and Without Intracoronary Nitrate Testing (NA)
- PericOronary INflammaTion in Non-Obstructive Coronary Artery Disease
- Impact of Cholesterol Level on Long-term Coronary Bypass Graft Patency
- Toripalimab Plus Actinomycin-D as Fist-Line Treatment for GTN With FIGO Score 5-6 (NA)
- Toripalimab Plus Actinomycin-D As Fist-Line Treatment for GTN with FIGO Score 7 (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- intravenous nitroglycerin CI brief — competitive landscape report
- intravenous nitroglycerin updates RSS · CI watch RSS
- University of California, San Francisco portfolio CI
Frequently asked questions about intravenous nitroglycerin
What is intravenous nitroglycerin?
How does intravenous nitroglycerin work?
What is intravenous nitroglycerin used for?
Who makes intravenous nitroglycerin?
What drug class is intravenous nitroglycerin in?
What development phase is intravenous nitroglycerin in?
What are the side effects of intravenous nitroglycerin?
What does intravenous nitroglycerin target?
Related
- Drug class: All Nitrate vasodilator drugs
- Target: All drugs targeting Soluble guanylate cyclase (via nitric oxide)
- Manufacturer: University of California, San Francisco — full pipeline
- Therapeutic area: All drugs in Cardiovascular
- Indication: Drugs for Acute angina pectoris
- Indication: Drugs for Acute myocardial infarction with chest pain
- Indication: Drugs for Hypertensive crisis
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing